We are live on
!
Find out more
ESPR
Esperion Therapeutics
ESPR
ESPR
Delisted
ESPR was delisted on the 10th of July, 2026.
157 hedge funds and large institutions have $803M invested in Esperion Therapeutics in 2020 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 52 increasing their positions, 52 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
0% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 52
2.93% less ownership
Funds ownership: 113.7% → 110.77% (-2.9%)
5% less funds holding
Funds holding: 166 → 157 (-9)
23% less call options, than puts
Call options by funds: $11.6M | Put options by funds: $15.1M
31% less capital invested
Capital invested by funds: $1.17B → $803M (-$364M)
35% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 26
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Holders
157
Holders Change
-9
Holders Change %
-5.42%
% of All Funds
2.78%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
17
Increased
52
Reduced
52
Closed
26
Calls
$11.6M
Puts
$15.1M
Net Calls
-$3.49M
Net Calls Change
-$9.93M
Top Buyers
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$47.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$21.6M |
| 3 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$20.9M |
| 4 |
Morgan Stanley
New York
|
+$6.01M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$5.1M |
